Welcome to our dedicated page for VIEMED HEALTHCARE SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare used a new investor presentation to highlight strong 2025 performance and 2026 guidance. For 2025, the company reported $270M in net revenue, $61M Adjusted EBITDA, $28M free cash flow, nine straight years of positive net income, and effectively $0M net debt.
The business is increasingly diversified, with sleep representing 21% of Q4 2025 net revenue and showing 62% year-over-year growth in PAP therapy patients and 49% growth in sleep resupply patients. Management is guiding 2026 net revenue to $310M–$320M and Adjusted EBITDA to $65M–$69M, with net capex of 10%–11.5% of net revenue.
The company emphasizes a capital-light, home-based care model, expanding from complex ventilation into sleep, oxygen, airway clearance, women’s health and staffing. With more than 172,000 patients across all 50 states, $46M of credit facility availability, and a newly authorized share repurchase program covering up to 5% of shares outstanding, Viemed presents itself as a growth platform supported by regulatory stability and a strong balance sheet.
Viemed Healthcare, Inc. outlines its 2025 annual business profile as a U.S. home medical equipment and post-acute care provider focused on respiratory, chronic care, and women’s health services. The company serves patients in all 50 states through a high-touch, technology-enabled home-care model.
Viemed employed 1,382 people as of December 31, 2025, including 401 licensed respiratory therapists. Monthly ventilator rentals generated about 51% of 2025 revenue, while Medicare and Medicaid together provided 40%. Non-affiliate market value was $238,786,569, with 38,602,631 common shares outstanding.
The report emphasizes heavy dependence on government and commercial reimbursement, extensive U.S. healthcare regulation, fraud and abuse laws, HIPAA privacy and cybersecurity obligations, and evolving Medicare coverage and competitive bidding rules that could materially affect utilization, pricing, and growth, especially for ventilator and home-based respiratory services.
Viemed Healthcare reported record 2025 results with net revenue of $270.3 million, up 21% from 2024, driven by organic growth and its Lehan's Medical Equipment acquisition. Net income attributable to Viemed rose 33% to $14.9 million, and Adjusted EBITDA reached a record $61.4 million.
The company generated strong free cash flow of $28.1 million for 2025, up sharply from $11.6 million, while ventilator, PAP therapy, and sleep resupply patient counts all increased. For 2026, Viemed guides net revenue to $310–$320 million and Adjusted EBITDA to $65–$69 million. The board also approved a new share repurchase program for up to 1,930,131 common shares, about 5% of shares outstanding, effective through March 2027.
Viemed Healthcare Chief Executive Officer and director Hoyt Casey reported equity compensation-related transactions on common shares dated January 29, 2026. He acquired 39,795 common shares through the vesting and settlement of Restricted Stock Units and 13,265 common shares tied to cash-settled phantom share units.
The company withheld 13,913 common shares at a per-share value of $7.48 to cover Casey’s tax obligations from RSU vesting, and 13,265 common shares were simultaneously disposed of to the company in connection with phantom share settlement. After these transactions, Casey directly owned 350,464 common shares and indirectly held 1,984,943 common shares through Elizabeth Rose Homes LLC.
Viemed Healthcare vice president of sales Jerome Cambre reported equity award vesting and related share movements. On January 29, 2026, 8,619 Restricted Stock Units converted into common shares and 2,873 phantom share units vested into common shares. To cover taxes from RSU vesting, the issuer withheld 2,355 common shares at a per-share value of $7.48, based on the market closing price that day. Following the reported transactions, Cambre directly held 104,088 Viemed common shares.
Viemed Healthcare president Michael Moore reported equity award vesting and related share movements. On January 29, 2026, 26,842 Restricted Stock Units converted into an equal number of common shares, and 8,947 phantom share units vested and were economically settled for common shares before being delivered back to the company for cash.
The issuer withheld 7,342 common shares at $7.48 per share to cover Moore’s tax obligations from the RSU vesting. After these transactions, Moore held 189,090 common shares directly and 1,722,614 common shares indirectly through Moore Faster LLC.
Viemed Healthcare’s General Counsel, Jeremy Trahan, reported equity award vesting and related share movements in company stock. On January 29, 2026, 10,774 restricted stock units converted into the same number of common shares, while 2,939 shares were withheld by the company to cover taxes at a value of $7.48 per share.
The filing also shows 3,591 cash-settled phantom share units vesting, economically equivalent to common shares and settled in cash with matching share movements. After these transactions, Trahan directly holds 46,492 common shares, plus 10,773 restricted stock units and 3,591 phantom share units as continuing equity interests.
Viemed Healthcare, Inc. Chief Medical Officer and director William Frazier reported equity award vesting and related share transactions. On January 29, 2026, 2,334 Restricted Stock Units converted into 2,334 common shares, and 778 phantom share units converted into 778 common shares, both at an exercise price of $0 per share.
To cover tax obligations from the RSU vesting, 802 common shares were withheld and disposed of at $7.48 per share, based on the closing market price on January 29, 2026. After these transactions and related dispositions, Frazier beneficially owned 73,214 common shares directly.
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity on January 29, 2026. A block of 9,794 restricted stock units converted into the same number of common shares, and 3,265 cash-settled phantom share units were settled into common shares under the company’s plans.
To cover tax obligations from the restricted stock vesting, 2,679 common shares were withheld by Viemed at a per‑share value of $7.48. In connection with the phantom share settlement, 3,265 common shares were delivered to and simultaneously surrendered back to the company for cash. After these transactions, Trae directly owned 105,638 common shares.
Viemed Healthcare, Inc. Chief Operating Officer and director William Todd Zehnder reported equity compensation vesting and related tax share dispositions. On January 29, 2026, 26,842 restricted stock units converted into an equal number of common shares, and 8,948 cash-settled phantom share units vested, each economically equivalent to one common share.
The company withheld 11,368 common shares at $7.48 per share and a further 8,948 common shares at the same price to cover tax obligations tied to these awards. After these transactions, Zehnder directly owned 390,309 common shares of Viemed Healthcare.